

REVIEW

The promise of circulating tumor cell analysis in cancer management

Joaquin Mateo^{1,2}, Marco Gerlinger^{3,4}, Daniel Nava Rodrigues^{1,2} and Johann S de Bono^{1,2*}

Abstract

Enumeration and molecular characterization of circulating tumor cells isolated from peripheral blood of patients with cancer can aid selection of targeted therapy for patients, monitoring of response to therapies and optimization of drug development, while also providing valuable information about intratumoral heterogeneity.

Introduction

With the advent of therapies that target the specific molecular aberrations driving a cancer, the traditional concept of 'one treatment fits all' is evolving to 'one patient, one treatment'. Furthermore, as tumors adapt to the selection pressures of serial targeted drugs through the evolution of drug-resistant clones, their genomic landscape changes over time, and hence treatments need to be tailored accordingly [1]. Thus, treatment strategies will almost invariably progress further to 'one patient at one moment in time, one treatment'.

The endeavor for precision medicine demands that each patient be molecularly characterized and that robust and validated 'real-time' assays are made in order to evaluate tumor evolution. Although the study of tumor biopsies or surgical specimens remains the 'gold standard' for molecular characterization in clinical trials testing a biomarker [2,3], single-sample analyses fail to represent the heterogeneous genomic evolution of tumors [4]. Considering the physical, logistical and ethical limitations of repeating multiple tumor biopsies in patients, biomarkers that could be judged through minimally invasive procedures, such as blood draws, constitute an opportunity for progression in precision medicine.

Circulating tumor cells (CTCs), which are shed into the bloodstream from solid tumors, are relatively rare, representing only one in more than a million blood cells [5]. Patients with metastatic cancer are more likely to have detectable CTCs in the bloodstream [6], but CTCs also exist in patients with localized disease, even after primary radical treatment, when their presence is informative of recurrence risk [7]. Although the presence of cancer cells in the systemic circulation of patients with solid tumors was recognized more than a century ago [8], it is only in the past two decades that the ability to isolate CTCs has enabled their molecular characterization and their use as prognostic and response biomarkers.

CTCs provide the opportunity to assess the biological features of cancer repeatedly during the evolution of the disease, enabling clinicians to react quickly to treat the patient with the most suitable specific targeted therapy.

Here, we review the clinical studies to date on the use of CTCs as biomarkers of cancer development and discuss the promise of CTC analysis to guide clinical decision-making and to aid targeted drug development.

Identification of circulating tumor cells: technical aspects


Methods to capture CTCs from blood rest on their differential physical or immunologic characteristics. The basis for affinity-binding systems used for CTC 'enrichment' is the selection of cells expressing certain antigens, such as epithelial cell-adhesion molecules (EpCAMs), and the discard of those cells expressing antigens that are known to be absent on epithelial cells but expressed by other blood cells, such as leukocyte-expressed CD45. Alternatively, CTCs can be isolated based on their distinct physical (size or deformability) or electromagnetic properties [9-11]. The enriched CTC population is then evaluated using an imaging system and, although counting can be completely automated, this step usually requires a certain degree of input from a human operator (Figure 1).

* Correspondence: johann.de-bono@icr.ac.uk

¹Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK

²Drug Development Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK

Full list of author information is available at the end of the article



In order to implement a biomarker into clinical practice, it is crucial to obtain analytical validation (assay sensitivity, specificity and predictive value must be robust and constant) and evidence of the clinical significance of any results obtained. In 2011, the semi-automated CellSearch system (Janssen Diagnostics) became the first US Food and Drug Administration-cleared assay for quantitative analysis of CTCs, based on its high reproducibility [5] and the prognostic value demonstrated in prostate, breast and colorectal cancer studies [12–14]. This platform selects CTCs from blood samples according to size, presence of a visible nucleus and markers of epithelial origin (EpCAM, CD8, CD18 and CD19 positivity and absence of CD45) [15].

There are several promising capture platforms in development; a separate article in this special issue comprehensively reviews the advances in isolation and characterization of CTCs [16]. Potential advantages offered by some of the methods in progress include: first, a lack of a need for protein-based enrichment with the Epic Sciences platform, which retains all nucleated cells and permits their study with a high-definition scanner, allowing for a more complex characterization of CTCs

and direct observation of 'clusters' of cells [17]; second, capturing higher amounts of CTCs with microfluidic platforms (CTC-chips) [18,19]; and, third, the possibility of continuous capturing of CTCs from blood by using detectors inserted into the patient's veins or apheresis-based approaches with subsequent *ex vivo* CTC isolation [20,21]. This last method enables the screening of CTCs over larger volumes of blood, which could be relevant for monitoring residual disease in early stages of cancer, when low counts are expected.

Clinical utility of circulating tumor cell counts

Prognostic value

The number of CTCs present in the bloodstream of patients with metastatic cancer is prognostic for overall survival in several tumor types, with robust evidence reported for prostate, breast and colorectal cancer [12–14].

In metastatic castration-resistant prostate cancer (mCRPC), the prognostic value of baseline CTC counts was first assessed in the IMMC38 trial, a study including 164 patients about to start first-line chemotherapy (81% received docetaxel, and the remainder received a docetaxel-containing regimen). A high count of CTCs at baseline (defined as ≥ 5 CTCs in 7.5 ml blood) was associated with a significantly shorter survival compared with having low counts at baseline (11.5 versus 21.7 months; $P < 0.0001$). CTC counts were better indicators of survival than levels of prostate-specific antigen (PSA) (Figure 2) [13,22]. Further clinical trials in mCRPC have confirmed these findings [23].

A study by Cristofanilli established the prognostic value of CTC counts in advanced breast cancer. Patients with metastatic breast cancer were tested for CTCs at the time of starting a new line of treatment (either hormonal, chemotherapy or other treatments; 83 patients were assessed before the first line of systemic treatment, whereas 92 had received previous therapies). Patients with ≥ 5 CTCs per 7.5 ml blood had the worst progression-free survival (2.7 months versus 10 months; $P < 0.001$) and overall survival (10.1 months versus >18 months; $P < 0.001$). In a multivariate analysis including several molecular and clinical prognostic factors, CTC counts were a strong independent prognostic factor [24].

In the setting of metastatic colorectal cancer, the prognostic significance of CTCs was prospectively evaluated in 430 patients before starting a new line of chemotherapy. Patients were stratified based on CTC levels of ≥ 3 versus < 3 per 7.5 ml blood. Patients in the 'unfavorable prognosis' group had shorter overall survival (9.4 months versus 18.5 months; $P < 0.001$) and progression-free survival (4.5 months versus 7.9 months; $P = 0.0002$) [14]. Pilati and colleagues also concluded that CTCs were prognostic in patients with liver-confined metastasis from




Figure 2 (See legend on next page.)

(See figure on previous page.)

Figure 2 Prognostic and predictive value of circulating tumor cell (CTC) counts in metastatic castration-resistant prostate cancer (mCRPC).

(a) Survival curves (Kaplan-Meier) of a group of 276 patients with mCRPC who were about to start a new line of chemotherapy, showing how patients with <5 CTCs per 7.5 ml blood ('favorable' CTC count; green line) had a better prognosis than the group of patients with higher counts (red line). **(b)** Differential survival curves representing outcomes for patients according to the change in their CTC counts after receiving treatment, which show that patients with a conversion from an 'unfavorable' to a 'favorable' count during the response to treatment (blue line) experience longer survival than those without a CTC drop (red and orange lines). The green line is the survival curves for those patients who have low CTC counts at the beginning of that study and whose counts remained low throughout the study. OS, overall survival; HR, Haza-ratio; CI, confidence interval. Reprinted from [13] de Bono JS et al. *Clin Cancer Res* 2008, 14:6302-6309. (Copyright by American Association for Cancer Research).

colorectal cancer candidates to receive savage liver surgery, suggesting that CTCs might help to stratify the management of this population [25].

Clinical validation of CTC counts as prognostic biomarkers is being pursued in advanced stages of other tumor types, with promising results reported in lung [26,27], melanoma [28], head and neck [29] or pancreatic cancer [30].

Moreover, CTCs have also been demonstrated to inform prognosis in earlier stages of the disease. A large study analyzed their presence in 735 patients with colorectal cancer undergoing surgery with curative intent. CTC enrichment selected cells expressing carcinoembryonic antigen, cytokeratin 19, cytokeratin 20 and/or CD-133. Time to relapse and overall survival was significantly poorer for those patients with detectable CTCs [31].

In early stages of breast cancer, CTCs were detected in 21.5% of 2,026 patients after surgery and before the start of adjuvant chemotherapy. The presence of CTCs in this population was an independent prognostic factor for disease-free and overall survival [32].

Overall, CTC enumeration is a strong prognostic tool in patients with advanced cancer and can help in patient stratification. In earlier stages of cancer, there is high hope that CTC enumeration could monitor residual disease after radical treatment, although the counts in this population would be generally low, and the analysis would require a platform with very high sensitivity.

Markers of response

Changes in CTC counts as a result of anticancer treatment have also been shown to be a reliable marker of response to treatment in different clinical settings. In mCRPC, the predictive value of changes in CTC counts and the correlation with survival have an enhanced relevance owing to the challenge of evaluating the response to treatment by standard radiological parameters as most of the metastatic disease is confined to the bones [33,34]. The IMMC38 study, mentioned above, was the first to correlate changes in CTC counts with clinical outcome in mCRPC: those patients with a baseline high CTC count that converted to a low count after chemotherapy had significantly better outcomes than those patients whose counts remained high despite the treatment

(Figure 2) [13]. These findings were later validated in the randomized phase III study that led to the approval of the CYP-17 inhibitor abiraterone (Zytiga, Janssen Biotech) [35].

Similarly, conversion from an unfavorable to favorable CTC count after 4 weeks of treatment (using a threshold of 5 CTC per 7.5 ml blood) is a predictive biomarker of response to first-line therapy for metastatic breast cancer (progression-free survival of 9.4 months compared with 4.9 months for patients with high CTC counts at baseline that remained high on therapy). Moreover, drops in CTC counts upon treatment correlated with improved overall survival [12]. CTCs offer an early readout of response to treatment (4 weeks) instead of having to wait until the appearance of changes in radiological biomarkers, which might happen later; a study in 138 women with metastatic breast cancer receiving different treatments compared the performance of CTCs (after 4 weeks of treatment) and radiological assessments (after 10 weeks), concluding that CTCs were a more robust marker of patient outcome, and with a lower rate of inter-reader variability in interpretation of results (0.7% versus 15%) [36].

The value of CTC counts on treatment as an independent marker of response is also well established in metastatic colorectal cancer [14]. The study from Cohen and colleagues confirmed that patients with low CTC counts upon therapy had extended progression-free and overall survival, and this predictive value was maintained when assessed at different time-points throughout the therapy. The cut-off value in this case for the favorable versus unfavorable prognosis groups was 3 CTCs per 7.5 ml blood.

Almost every study judging CTC counts as response markers in different cancer types has simplified the enumeration to a dichotomist variable (high or low count) by using particular thresholds in different tumor types instead of considering CTC counts as a continuous variable; a combined analysis of CTC counts from 111 patients with metastatic breast cancer and 185 with mCRPC who participated in the IMMC-01 and IMMC-38 clinical trials [13,24] supports this strategy [37]. A study in mCRPC patients suggested that a relative decrease (30%) from baseline CTC counts

remains predictive of response in univariate and multivariate analyses [38].

Molecular characterization of tumors from circulating tumor cells

Molecular profiling of circulating tumor cells

CTCs represent a valuable resource for studying the molecular underpinnings of cancer in individual patients. CTC analysis can support the delivery of precision anti-cancer treatments, as specific biomarkers of response to targeted drugs can be appraised.

Genomic- and proteomic-based assays can be used to analyze CTCs and detect the presence or absence of key signaling oncogenic aberrations. For instance, cytogenetic studies based on fluorescence *in situ* hybridization have been used to describe the variability between CTCs, tumor metastasis and primary prostatic cancers in copy-number aberrations for the androgen receptor and presence of TMPRSS2-ERG fusions and loss of the tumor suppressor gene *PTEN* (encoding phosphatase and tensin homolog) [39].

An example of how transcriptome studies in CTC analysis can be clinically applicable was the assessment, by RNA *in situ* hybridization studies, of how relative changes during treatment in the expression of epithelial and mesenchymal markers in CTCs from 11 patients with metastatic breast cancer correlated with response and prognosis [40].

As a result of recent progress in next-generation sequencing techniques, it is now also possible to perform whole-genome and transcriptome amplification from single cells, such as CTCs [41]. Lohr and colleagues were able to isolate single CTCs expressing PSA (assessed by low-coverage single-cell RNA sequencing) from patients with metastatic prostate cancer and sequenced the whole-exome [42] despite the limited input material that can be obtained from single CTCs, which remains the main challenge for such studies [43]. In the field of transcriptome assays, Ramsköld and collaborators developed a platform for efficient and robust single-cell RNA sequencing. In a cohort of samples from patients with advanced melanoma (a tumor of non-epithelial origin and therefore in which EpCAM-based cell selection is not useful), these investigators were able to analyze the transcriptome from single CTCs expressing melanoma markers [44].

Treatment selection and monitoring of drug resistance

As cancer subclonal composition and driver mutation landscapes can change through the outgrowth of drug-resistant subclones after exposure to systemic therapy, it might also be important to assess whether predictive biomarkers are present at the specific time of starting a new line of targeted treatment, contrary to testing biopsies taken at earlier stages of the natural history of the

disease; a study on 254 patients with breast cancer was able to detect overexpression of human epidermal growth factor receptor 2 (HER2) in CTCs in almost one-third of patients who had no HER2 overexpression in the primary tumor [45]. This finding has tremendous clinical relevance as overexpression of HER2 is a clinically validated predictive biomarker of response to HER2-targeting therapies in breast cancer [46,47].

A proof-of-principle study in lung cancer detected activating mutations in the gene encoding the epidermal growth factor receptor (EGFR) in CTCs from 11 out of the 12 patients tested; these patients were receiving EGFR-targeting tyrosine kinase inhibitors, and interestingly some of these mutations in CTCs had emerged *de novo* (that is, were not present in the matched primary tumor), suggestive of temporal evolution and a putative acquired mechanism of resistance to therapy [48]. Analogous results in patients with metastatic melanoma receiving serine/threonine-protein kinase B-Raf (BRAF) inhibitors, colorectal cancers patients treated with anti-EGFR antibodies and patients with gastrointestinal stromal tumors during tyrosine-protein kinase Kit/alpha-type platelet-derived growth factor receptor (KIT/PDGFR)-targeting treatment [49-52] support performing real-time analysis of predictive biomarkers of response in cancer medicine, and minimally invasive CTC-based studies represent an advance compared with tumor biopsy samples for repetitive, real-time analysis.

Ideally, patients would start a targeted treatment, and molecular indicators of response or resistance would be assessed in CTCs and/or other circulating biomarkers repeatedly over the course of treatment, guiding clinicians regarding when to stop or switch the anticancer treatment. A recent and successful example of this strategy is a study that serially characterized CTCs from 58 patients with mCRPC while receiving either enzalutamide or abiraterone to study mechanisms of resistance; quantitative reverse-transcription polymerase chain reaction was utilized to interrogate the presence of splice variants of the androgen receptor genes in CTCs. Antonarakis and colleagues demonstrated that the splice variant 7 of the androgen receptor (AR-V7) is a predictive factor of enzalutamide or abiraterone failure and, more interestingly, that the appearance of AR-V7 during the course of treatment in patients with no AR-V7 expression at baseline might be a mechanism of acquired resistance to these drugs [53].

Circulating tumor cell analysis to understand intratumor heterogeneity

Genetic intra-tumor heterogeneity (ITH) has been discovered across a wide range of solid tumor types. For example, exome sequencing of multiple tumor regions from clear-cell kidney tumors, the commonest type of renal

cancer, revealed that, on average, only one-third of the somatic mutations and DNA copy-number aberrations detected were present in every region that was analyzed from an individual tumor [54]. Mutations or hypermethylation of the *VHL* gene and loss of heterozygosity of chromosome 3p were the only aberrations detected in all analyzed regions from each tumor, suggesting that these were early founder aberrations, whereas other molecular aberrations, including mutations in members of the phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway (that is, mTOR, TSC2, PTEN and PIK3CA) amenable to be targeted with specific drugs, were heterogeneous within individual tumors. Genetic ITH has also been identified across many other solid tumor types such as primary breast, gastric, bladder, prostate and pancreatic cancers, where various degrees of genetic ITH, ranging from intermixed subclones to spatially separated subclones, have been described [54-58].

Integrating ITH in individualized treatment selections remains an unmet clinical need in cancer medicine. Sequencing studies on CTCs allow heterogeneous mutations to be captured, enabling a more detailed picture of ITH and subclonal evolution in a single patient with a minimally invasive approach. It is envisioned that the analysis of subclonal heterogeneity could help clinicians to understand why cancer patients might not respond homogeneously in different metastases to treatment with a targeted drug and might eventually guide treatment selection.

Using CTCs for ITH studies facilitates the inference of subclonal structures. Genomic-profiling studies of individual CTCs isolated from patients with metastatic colorectal cancer using the CellSearch platform showed how the presence of some genomic aberrations in CTCs was indicative of their subclonal origin from specific areas of the original tumor, through array-comparative genomic hybridization and multiplexed targeted sequencing of 68 genes relevant to colorectal cancer [41]. CTCs also further permit the study of gene-expression signatures, including dynamic drug-induced changes [59]. The functional interrogation of CTCs might provide crucial insights into the phenotypes of heterogeneous tumor subclones.

Circulating tumor cell studies to guide drug development


Pharmacodynamics (PD) studies are crucial in modern drug development to provide evidence for proof-of-mechanism in early-phase clinical trials and support 'go/no go' decisions about further development of new compounds. Minimally invasive access to CTCs from patients offers a unique opportunity to monitor the PD effect of drugs in phase I clinical trials [60].

Assessment of PD biomarkers in CTCs can be performed repeatedly over the course of treatment, which

represents an advantage compared with the study of tumor biopsies. To serve as an example, Wang and colleagues developed a quantitative assay to monitor changes in nuclear levels of the DNA damage marker histone variant γ H2AX in CTCs that they then tested in samples from 15 patients with different cancer types participating in diverse phase I trials [61]. Among them, an increase in the nuclear γ H2AX of CTCs as a response to therapy was observed in five patients receiving DNA-repair targeting drugs (topotecan, cyclophosphamide and/or inhibitors of the poly (ADP-ribose) polymerase PARP). Later, a phase I study of the PARP inhibitor Niraparib (MK-4827; Merck/Tesaro) implemented quantitative (changes in CTC counts over the course of treatment) and qualitative assessment of CTCs (nuclear γ H2AX expression) as exploratory endpoints to support preliminary signs of antitumor activity [62]. In this study of Niraparib, 21 patients with mCRPC were treated, with no radiological responses observed; however, several patients had significant drops in CTC counts, which were especially remarkable in the three patients with a time-to-progression of over 6 months.

Variations in CTC counts after drug exposure can also provide an easy and rapid readout of PD effects: the phase I trials of ARQ197 (a selective inhibitor of the hepatocyte growth factor receptor c-MET) in patients with different tumor types and EZN4176 (a second-generation antisense oligonucleotide to exon 4 of the androgen receptor) in prostate cancer assessed the changes in CTC counts in patients in parallel to the determination of the optimal doses of the drugs [63,64] (Figure 3). Precisely in the setting of phase I clinical trials, where patients with advanced stages of different tumor types and commonly a short survival expectancy are exposed to novel therapies, baseline CTC enumeration is of value as an independent prognostic factor and improves the performance of prognostic indexes used in clinical practice to select patients for these studies [65].

CTC analysis in early clinical trials can also be used to assess putative predictive biomarkers of response to novel targeted treatment and to provide proof-of-mechanism of novel compounds and a definition of biologically active doses. Hotspot mutations in PIK3CA were identified in CTCs from patients with either colorectal or breast cancer in two different studies [66,67]. Moreover, Kallergi and collaborators [68] were able to assess the activation of the PI3K-AKT-mTOR pathway in two groups of patients with early ($n = 16$) and metastatic ($n = 16$) breast cancer, reporting high expression levels of phospho-PI3K and phospho-AKT in CTCs from both populations. These results open the door to implementing such assays for patient selection in trials testing drugs against this important oncogenic signaling pathway, as has been done previously with tumor-tissue-based assays [69].



Conclusions and future directions

CTC analysis is a validated method to study tumor characteristics and aid clinical decision-making. This minimally invasive approach facilitates repetitive analysis over time. Analysis can be purely quantitative, which has been proven to deliver prognostic and predictive information at different stages of cancer, or can involve the assessment of molecular biomarkers in CTCs. It is crucial that the novel isolation platforms currently in development are analytically and clinically validated to ensure biomarker integrity.

One caveat for CTC studies is whether the whole burden of disease contributes equally to the CTC pool or whether some subclones of the disease might be under-represented or absent in CTCs. Additionally, it is also important to remember that the CellSearch system and other enrichment platforms based on epithelial markers might fail to recognize cells shed from non-epithelial cancers such as melanomas or sarcomas, in which disease-specific technologic approaches and composite selection criteria might be needed [70], or cells that have lost expression of epithelial markers owing to undergoing an epithelial-mesenchymal transition, a central part of the invasion-metastasis process [71,72].

Molecular characterization of CTCs to guide rational treatment selection has direct applicability in clinical practice; it can help to overcome the inability of single biopsies to portray accurately the genomic landscapes of cancers and the limitations of multi-metastasis biopsy approaches. The possibility of regularly re-assessing evolving cancers is extremely useful for on-going treatment stratification and understanding primary and secondary drug-resistance.

Nevertheless, the exact role of CTC counts in routine clinical practice remains yet to be defined. On the one hand, the costs and complexity associated with the

enrichment and enumeration process (including kits and operator time) are still high. On the other, a first clinical trial evaluating the benefit from an early switch on systemic treatment guided by changes in CTC counts after the first cycle of treatment in metastatic breast cancer recently failed to demonstrate significant benefit for this strategy compared with maintaining treatment until progression based on traditional endpoints [73]. However, the strong prognostic and predictive value demonstrated for CTCs in different tumor types and stages of the disease warrants further evaluation as a surrogate marker of survival endpoints in other clinical scenarios, which could change not only clinical practice but also the way clinical trials are designed. Thus, overall, quantitative and qualitative studies of CTCs represent a promising tool to advance toward the delivery of precision medicine to cancer patients.

Abbreviations

APC: Aallophycocyanin; AR-V7: Splice variant 7 of the androgen receptor; BRAF: Serine/threonine-protein kinase B-Raf; CI: Confidence interval; CTC: Circulating tumor cell; EGFR: Epidermal growth factor receptor; EpCAM: Epithelial cell-adhesion molecule; HER2: Human epidermal growth factor receptor 2; HR: Hazara-ratio; ITH: Intra-tumor heterogeneity; mCRPC: metastatic castration-resistant prostate cancer; OS: Overall survival; PD: Pharmacodynamics; PDGFR: Platelet-derived growth factor receptor; PE: Phycoerythrin; PSA: Prostate-specific antigen.

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

The Drug Development Unit of the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research is supported in part by a program grant from Cancer Research UK. Support was also provided by the Experimental Cancer Medicine Centre (to The Institute of Cancer Research) and the National Institute for Health Research Biomedical Research Centre (jointly to the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research).

Author details

¹Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK. ²Drug Development Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK. ³Centre for Evolution and Cancer, The Institute of Cancer Research, 123 Old Brompton Road, London SW7 3RP, UK. ⁴Gastrointestinal Cancer Unit, Department of Medicine, The Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, UK.

Published online: 30 August 2014

References

- Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B: **The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.** *Nature* 2012, **486**:537–540.
- Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au H-J, Langer C, Moore MJ, Zalberg JR: **K-ras mutations and benefit from cetuximab in advanced colorectal cancer.** *N Engl J Med* 2008, **359**:1757–1765.
- Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CDM, Ryan CW, von Mehren M, Blanke CD, Rankin C, Benjamin RS, Bramwell VH, Demetri GD, Bertagnoli MM, Fletcher JA: **Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Gr.** *J Clin Oncol* 2008, **26**:5360–5367.
- Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C: **Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.** *N Engl J Med* 2012, **366**:883–892.
- Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AGJ, Uhr JW, Terstappen LWMM: **Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.** *Clin Cancer Res* 2004, **10**:6897–6904.
- Tanaka F, Yoneda K, Kondo N, Hashimoto M, Takuwa T, Matsumoto S, Okumura Y, Rahman S, Tsubota N, Tsujimura T, Kuribayashi K, Fukuoka K, Nakano T, Hasegawa S: **Circulating tumor cell as a diagnostic marker in primary lung cancer.** *Clin Cancer Res* 2009, **15**:6980–6986.
- Hofman V, Bonnetaud C, Ilie MI, Vielh P, Vignaud JM, Fléjou JF, Lantuejoul S, Piaton E, Mourad N, Butori C, Selva E, Poudenx M, Sibon S, Kelhef S, Vénissac N, Jais J-P, Mouroux J, Molina TJ, Hofman P: **Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker.** *Clin Cancer Res* 2011, **17**:827–835.
- Ashworth TR: **A case of cancer in which cells similar to those in the tumours were seen in the blood after death.** *Aust Med J* 1869, **14**:146–147.
- Desitter I, Guerrouahen BS, Benali-Furet N, Wechsler J, Jänne PA, Kuang Y, Yanagita M, Wang L, Berkowitz JA, Distel RJ, Cayre YE: **A new device for rapid isolation by size and characterization of rare circulating tumor cells.** *Anticancer Res* 2011, **31**:427–441.
- Tan SJ, Yobas L, Lee GYH, Ong CN, Lim CT: **Microdevice for the isolation and enumeration of cancer cells from blood.** *Biomed Microdevices* 2009, **11**:883–892.
- Baker MK, Mikhitarian K, Osta W, Callahan K, Hoda R, Brescia F, Kneuper-Hall R, Mitas M, Cole DJ, Gillanders WE: **Molecular detection of breast cancer cells in the peripheral blood of advanced-stage breast cancer patients using multimarker real-time reverse transcription-polymerase chain reaction and a novel porous barrier density gradient centrifugation technology.** *Clin Cancer Res* 2003, **9**:4865–4871.
- Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LWMM: **Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.** *J Clin Oncol* 2005, **23**:1420–1430.
- De Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LWMM, Pienta KJ, Raghavan D: **Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.** *Clin Cancer Res* 2008, **14**:6302–6309.
- Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LWMM, Meropol NJ: **Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.** *J Clin Oncol* 2008, **26**:3213–3221.
- Kraan J, Sleijfer S, Strijbos MH, Ignatiadis M, Peeters D, Pierga J-Y, Farace F, Riethdorf S, Fehm T, Zorzino L, Tibbe AGJ, Maestro M, Gisbert-Criado R, Denton G, de Bono JS, Dive C, Foekens J, Gratama JW: **External quality assurance of circulating tumor cell enumeration using the Cell Search(®) system: a feasibility study.** *Cytom Part B* 2011, **80B**:112–118.
- Navin NE: **Cancer genomics: one cell at a time.** *Genome Biol* 2014, **15**:452.
- Marrinucci D, Bethel K, Kolatkar A, Luttgens MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P: **Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers.** *Phys Biol* 2012, **9**:016003.
- Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulluk S, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M: **Isolation of rare circulating tumour cells in cancer patients by microchip technology.** *Nature* 2007, **450**:1235–1239.
- Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen P, Morgan B, Trautwein J, Kimura A, Balis UJ, Tompkins RG, Haber DA, Toner M: **Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.** *Sci Transl Med* 2013, **5**:179ra47.
- Eifler RL, Lind J, Falkenhagen D, Weber V, Fischer MB, Zeillinger R: **Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept.** *Cytom B Clin Cytom* 2011, **80**:100–111.
- Saucedo-Zeni N, Mewes S, Niestroj R, Gasiorowski L, Murawa D, Nowaczyk P, Tomasi T, Weber E, Dworacki G, Morgenthaler NG, Jansen H, Propping C, Sterzynska K, Dyszkiewicz W, Zabel M, Kiechle M, Reuning U, Schmitt M, Lücke K: **A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire.** *Int J Oncol* 2012, **41**:1241–1250.
- Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G: **Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.** *Lancet Oncol* 2009, **10**:233–239.
- Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Datar RH, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Thompson IM, Cote RJ, Vogelzang NJ: **Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without abiraterone for metastatic castration-resistant prostate cancer.** *J Clin Oncol* 2014, **32**:1136–1142.
- Cristofanilli M: **Circulating tumor cells, disease progression, and survival in metastatic breast cancer.** *N Engl J Med* 2004, **351**:781–791.
- Pilati P, Mocellin S, Bertazza L, Galdi F, Briarava M, Mammano E, Tessari E, Zavagno G, Nitti D: **Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis.** *Ann Surg Oncol* 2012, **19**:402–408.
- Krebs MG, Sloane R, Priest L, Lancashire L, Hou J-M, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G, Ranson M, Dive C, Blackhall FH: **Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer.** *J Clin Oncol* 2011, **29**:1556–1563.
- Hiltermann TJN, Pore MM, van den Berg A, Timens W, Boezen HM, Liesker JJW, Schouwink JH, Wijnands WJA, Kerner GSMA, Kruyt FAE, Tissing H, Tibbe AGJ, Terstappen LWMM, Groen HJM: **Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor.** *Ann Oncol* 2012, **23**:2937–2942.
- Rao C, Bui T, Connelly M, Doyle G, Karydis I, Middleton MR, Clack G, Malone M, Coumans FAW, Terstappen LWMM: **Circulating melanoma cells and survival in metastatic melanoma.** *Int J Oncol* 2011, **38**:755–760.

29. Nichols AC, Lowes LE, Szeto CCT, Basmaji J, Dhaliwal S, Chapeskie C, Todorovic B, Read N, Venkatesan V, Hammond A, Palma DA, Winquist E, Ernst S, Fung K, Franklin JH, Yoo J, Koropatnick J, Mymryk JS, Barrett JW, Allan AL: **Detection of circulating tumor cells in advanced head and neck cancer using the Cell Search system.** *Head Neck* 2012, **34**:1440–1444.
30. Han L, Chen W, Zhao Q: **Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis.** *Tumour Biol* 2014, **35**:2473–2480.
31. Iinuma H, Watanabe T, Mimori K, Adachi M, Hayashi N, Tamura J, Matsuda K, Fukushima R, Okinaga K, Sasako M, Mori M: **Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.** *J Clin Oncol* 2011, **29**:1547–1555.
32. Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, Friedl TWP, Lorenz R, Tesch H, Fasching PA, Fehm T, Schneeweiss A, Lichtenegger W, Beckmann MW, Friese K, Pantel K, Janni W: **Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.** *J Natl Cancer Inst* 2014, **106**:dju066.
33. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bublely GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M: **Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.** *J Clin Oncol* 2008, **26**:1148–1159.
34. Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, Perrotte P, Montorsi F, Briganti A, Trinh Q-D, Karakiewicz PI, Sun M: **Distribution of metastatic sites in patients with prostate cancer: a population-based analysis.** *Prostate* 2014, **74**:210–216.
35. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, et al: **Abiraterone and increased survival in metastatic prostate cancer.** *N Engl J Med* 2011, **364**:1995–2005.
36. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LWMM, Hayes DF: **Circulating tumor cells versus imaging - predicting overall survival in metastatic breast cancer.** *Clin Cancer Res* 2006, **12**:6403–6409.
37. Coumans FAW, Ligthart ST, Terstappen LWMM: **Interpretation of changes in circulating tumor cell counts.** *Trans Onc* 2012, **5**:486–491.
38. Olmos D, Arkenau H-T, Ang JE, Ledaki I, Attard G, Carden CP, Reid AHM, A'Hern R, Fong PC, Oomen NB, Molife R, Dearnaley D, Parker C, Terstappen LWMM, de Bono JS: **Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.** *Ann Oncol* 2009, **20**:27–33.
39. Attard G, Swennenhuis JF, Olmos D, Reid AHM, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LWMM, de Bono JS: **Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.** *Cancer Res* 2009, **69**:2912–2918.
40. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S: **Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition.** *Science* 2013, **339**:580–584.
41. Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, Lax S, Waldspuehl-Geigl J, Mauerhammer O, Lackner C, Höfler G, Eisner F, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl JB, Speicher MR: **Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing.** *Cancer Res* 2013, **73**:2965–2975.
42. Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, Francis JM, Zhang C-Z, Shalek AK, Satija R, Trombetta JJ, Lu D, Tallapragada N, Tahirou N, Kim S, Blumenstiel B, Sougnez C, Lowe A, Wong B, Auclair D, Van Allen EM, Nakabayashi M, Lis RT, Lee G-SM, Li T, Chabot MS, Ly A, Taplin M-E, Clancy TE, Loda M, et al: **Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer.** *Nat Biotech* 2014, **32**:479–484.
43. Swennenhuis JF, Reumers J, Thys K, Aerssens J, Terstappen LW: **Efficiency of whole genome amplification of single circulating tumor cells enriched by Cell Search and sorted by FACS.** *Genome Med* 2013, **5**:106.
44. Ramsköld D, Luo S, Wang Y-C, Li R, Deng Q, Faridani OR, Daniels GA, Khrebtkova I, Loring JF, Laurent LC, Schroth GP, Sandberg R: **Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells.** *Nature* 2012, **30**:777–782.
45. Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Löhberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K: **HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.** *Breast Cancer Res Treat* 2010, **124**:403–412.
46. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonte A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: **Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.** *N Engl J Med* 2001, **344**:783–792.
47. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D: **Lapatinib plus capecitabine for HER2-positive advanced breast cancer.** *N Engl J Med* 2006, **355**:2733–2743.
48. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber DA: **Detection of mutations in EGFR in circulating lung-cancer cells.** *N Engl J Med* 2008, **359**:366–377.
49. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riey GJ: **Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.** *Clin Cancer Res* 2013, **19**:2240–2247.
50. Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M, McKenna A, Cibulskis K, Farlow D, Zimmer L, Hillen U, Gutzmer R, Goldinger SM, Ugurel S, Gogas HJ, Egberts F, Berking C, Trefzger U, Loquai C, Weide B, Hassel JC, Gabriel SB, Carter SL, Getz G, et al: **The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.** *Cancer Discov* 2014, **4**:94–109.
51. Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A: **Acquired resistance to EGFR-targeted therapies in colorectal cancer.** *Mol Oncol* 2014. doi:10.1016/j.molonc.2014.05.003.
52. Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, Fletcher CDM, Corless CL, Fletcher JA: **Heterogeneity of kinase inhibitor resistance mechanisms in GIST.** *J Pathol* 2008, **216**:64–74.
53. Antonarakis ES, Lu C, Wang H, Lubber B, Nakazawa M, Chen Y, Roeser J, Fedor HL, Lotan TL, Zheng Q, DeMarzo AM, Isaacs JT, Isaacs WB, Nadal R, Pallar C, Denmeade SR, Carducci M, Eisenberger MA, Luo J: **Androgen receptor splice variant-7 (AR-V7) predicts resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer.** *J Clin Oncol* 2014, **32**(suppl). abstract 5001.
54. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos CR, Martinez P, Phillimore B, Begum S, Rabinowitz A, Spencer-Dene B, Gulati S, Bates PA, Stamp G, Pickering L, Gore M, Nicol DL, Hazell S, Futreal PA, Stewart A, Swanton C: **Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.** *Nat Gen* 2014, **46**:225–233.
55. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, et al: **The clonal and mutational evolution spectrum of primary triple-negative breast cancers.** *Nature* 2012, **486**:395–399.
56. Diaz-Cano SJ, Blanes A, Rubio J, Matilla A, Wolfe HJ: **Molecular evolution and intratumor heterogeneity by topographic compartments in muscle-invasive transitional cell carcinoma of the urinary bladder.** *Lab Invest* 2000, **80**:279–289.
57. Attard G, Jameson C, Moreira J, Flohr P, Parker C, Dearnaley D, Cooper CS, de Bono JS: **Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity.** *J Clin Pathol* 2009, **62**:373–376.
58. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin M-L, McBride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Griffin CA, Burton J,

- Swerdlow H, Quail MA, Stratton MR, Iacobuzio-Donahue C, Futreal PA: **The patterns and dynamics of genomic instability in metastatic pancreatic cancer.** *Nature* 2010, **467**:1109–1113.
59. Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu C-L, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber DA: **Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.** *Cancer Discov* 2012, **2**:995–1003.
60. Yap TA, Sandhu SK, Workman P, de Bono JS: **Envisioning the future of early anticancer drug development.** *Nat Rev Cancer* 2010, **10**:514–523.
61. Wang LH, Pfister TD, Parchment RE, Kummar S, Rubinstein L, Evrard YA, Gutierrez ME, Murgu AJ, Tomaszewski JE, Doroshow JH, Kinders RJ: **Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells.** *Clin Cancer Res* 2010, **16**:1073–1084.
62. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreisler N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM: **The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.** *Lancet Oncol* 2013, **2045**:1–11.
63. Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, Pope L, Clark J, Futreal A, Germuska M, Collins D, DeSouza NM, Leach MO, Savage RE, Waghorne C, Chai F, Garmey E, Schwartz B, Kaye SB, de Bono JS: **Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.** *J Clin Oncol* 2011, **29**:1271–1279.
64. Bianchini D, Omlin A, Pezaro C, Mukherji D, Lorente Estelles D, Zivi A, Ferraldeschi R, Crespo M, Buchbinder A, Attard G, Scher HI, de Bono JS, Danila DC: **First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide (LNA-ASO) to androgen receptor (AR) mRNA in patients with castration-resistant prostate cancer (CRPC) [abstract].** *J Clin Oncol* 2013, **31**(suppl). abstract 5052.
65. Olmos D, Baird RD, Yap TA, Massard C, Pope L, Sandhu SK, Attard G, Dukes J, Papadatos-Pastos D, Grainger P, Kaye SB, de Bono JS: **Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials.** *Clin Cancer Res* 2011, **17**:5188–5196.
66. Gasch C, Bauernhofer T, Pichler M, Langer-Freitag S, Reeh M, Seifert AM, Mauermann O, Izbicki JR, Pantel K, Riethdorf S: **Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.** *Clinical Chem* 2013, **59**:252–260.
67. Schneck H, Blassi C, Meier-Stiegen F, Neves RP, Janni W, Fehm T, Neubauer H: **Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer.** *Mol Oncol* 2013, **7**(5):976–986.
68. Kallergi G, Agelaki S, Kalykaki A, Stounaras C, Mavroudis D, Georgoulas V: **Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients.** *Breast Cancer Res* 2008, **10**(5):R80.
69. Ong M, Carreira S, Goodall J, Mateo J, Figueiredo I, Rodrigues DN, Perkins G, Seed G, Yap TA, Attard G, de Bono JS: **Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.** *Br J Cancer* 2014. doi:10.1038/bjc.2014.350 [Epub ahead of print].
70. Coumans FA, Ligthart ST, Uhr JW, Terstappen LWMM: **Challenges in the enumeration and phenotyping of CTC.** *Clin Cancer Res* 2012, **18**:5711–5718.
71. Tomaskovic-Crook E, Thompson EW, Thiery JP: **Epithelial to mesenchymal transition and breast cancer.** *Breast Cancer Res* 2009, **11**:213.
72. Kalluri R: **EMT: when epithelial cells decide to become mesenchymal-like cells.** *J Clin Invest* 2009, **119**:1417–1419.
73. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF: **Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.** *J Clin Oncol* 2014, **32**:1–8.

doi:10.1186/s13059-014-0448-5

Cite this article as: Mateo et al.: The promise of circulating tumor cell analysis in cancer management. *Genome Biology* 2014 **15**:448.